1-3 of 3
Michelle Little
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Reducing Time Toxicity for Anti-B-Cell Maturation Antigen (BCMA) Bispecific Treatment: Evidence from Pivotal Single-Arm Trial Data on Teclistamab, Elranatamab, and Linvoseltamab for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, Timothy J. Inocencio, Zheng-Yi Zhou, Michael K. Xu, Jack Eales, Michelle Little, Peter Quon, Qiufei Ma
Journal: Blood
Blood (2024) 144 (Supplement 1): 2271.
https://doi.org/10.1182/blood-2024-199182
Published: 2024
Journal Articles

Treatment Patterns and Survival Outcomes of Patients with Acute Myeloid Leukemia Who Achieved Remission in the Connect ® Myeloid Disease Registry

Gail J. Roboz, Mehrdad Abedi, Michael A. Thompson, Mikkael A. Sekeres, Daniel A. Pollyea, Karen Seiter, Edward Yu, Pavel Kiselev, Michelle Little, Irina Fernandez, Irene S. DeGutis, Harry P. Erba
Journal: Blood
Blood (2021) 138 (Supplement 1): 279.
https://doi.org/10.1182/blood-2021-145849
Published: 2021
Journal Articles

Post-Remission Treatment (Tx) Patterns for Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the Connect ® MDS/AML Disease Registry

Gail J. Roboz, MD, Christopher R. Cogle, Daniel A. Pollyea, Mehrdad Abedi, MD, Michael A. Thompson, MD PhD, Melissa Nifenecker, E. Dawn Flick, Pavel Kiselev, Chrystal U. Louis, Michelle Little, Harry P. Erba
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–27.
https://doi.org/10.1182/blood-2020-135877
Published: 2020